Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1) → 4-chloro-2-fluoro-5-[4-(3-fluorophenyl)-4-[2-[(1R,5S)-3-(2-methylbenzimidazol-1-yl)-8-azabicyclo[3.2.1]octan-8-yl]ethyl]piperidine-1-carbonyl]-N-isopropyl-benzenesulfonamide

Participants

Reaction Steps

0.290 g (0.65 mmol) 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole and 0.288 g (0.975 mmol) 2-chloro-4-fluoro-5-[(isopropylamino)sulfonyl]benzoic acid were combined following the HATU general procedure in Example 5. This compound was purified by reverse phase chromatography on a 0-100% gradient of 0.1% TFA in water in acetonitrile. 0.196 g obtained (42% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.09-8.19 (m, 1H), 7.76-7.99 (m, 2H), 7.38-7.55 (m, 4H), 7.25-7.31 (m, 1H), 7.07-7.20 (m, 3H), 4.52-4.62 (m, 1H), 3.92-4.01 (m, 1H), 3.29-3.43 (m, 6H), 3.01-3.11 (m, 1H), 2.76 (s, 1H), 2.47-2.51 (m, 2H), 2.36-2.45 (m, 1H), 1.78-2.04 (m, 12H), 1.25-1.32 (m, 3H), 0.99-1.07 (m, 6H).

Provenance & Evidence